Gene specific therapies: the next therapeutic milestone in neurology
Gene selective approaches that either correct a disease mutation or a pathogenic mechanism will fundamentally change the treatment of neurological disorders. Basically, gene specific therapies are designed to manipulate RNA expression or reconstitute gene expression and function depending on the dis...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2020 Sept. 8
|
| In: |
Neurological research and practice
Year: 2020, Volume: 2, Pages: 1-13 |
| ISSN: | 2524-3489 |
| DOI: | 10.1186/s42466-020-00075-z |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s42466-020-00075-z Verlag, lizenzpflichtig, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650126/ 
|
| Author Notes: | David Brenner, Albert C. Ludolph and Jochen H. Weishaupt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1753282519 | ||
| 003 | DE-627 | ||
| 005 | 20230426165449.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210407s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s42466-020-00075-z |2 doi | |
| 035 | |a (DE-627)1753282519 | ||
| 035 | |a (DE-599)KXP1753282519 | ||
| 035 | |a (OCoLC)1341403632 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Brenner, David |d 1986- |e VerfasserIn |0 (DE-588)1077188838 |0 (DE-627)836099753 |0 (DE-576)446029262 |4 aut | |
| 245 | 1 | 0 | |a Gene specific therapies |b the next therapeutic milestone in neurology |c David Brenner, Albert C. Ludolph and Jochen H. Weishaupt |
| 264 | 1 | |c 2020 Sept. 8 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.04.2021 | ||
| 520 | |a Gene selective approaches that either correct a disease mutation or a pathogenic mechanism will fundamentally change the treatment of neurological disorders. Basically, gene specific therapies are designed to manipulate RNA expression or reconstitute gene expression and function depending on the disease mechanism. Considerable methodological advances in the last years have made successful clinical translation of gene selective approaches possible, based on RNA interference or viral gene reconstitution in spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and familial amyloid polyneuropathy (FAP). In this review, we provide an overview of the existing and coming gene specific therapies in neurology and discuss benefits, risks and challenges. | ||
| 700 | 1 | |a Ludolph, Albert C. |d 1953- |e VerfasserIn |0 (DE-588)1081317531 |0 (DE-627)845970100 |0 (DE-576)454116195 |4 aut | |
| 700 | 1 | |a Weishaupt, Jochen H. |d 1971- |e VerfasserIn |0 (DE-588)122148924 |0 (DE-627)705789039 |0 (DE-576)293117810 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological research and practice |d [London] : BioMed Central, 2019 |g 2(2020), Artikel-ID 25, Seite 1-13 |h Online-Ressource |w (DE-627)1038162947 |w (DE-600)2947493-0 |w (DE-576)512479968 |x 2524-3489 |7 nnas |a Gene specific therapies the next therapeutic milestone in neurology |
| 773 | 1 | 8 | |g volume:2 |g year:2020 |g elocationid:25 |g pages:1-13 |g extent:13 |a Gene specific therapies the next therapeutic milestone in neurology |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s42466-020-00075-z |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650126/ |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210407 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 122148924 |a Weishaupt, Jochen H. |m 122148924:Weishaupt, Jochen H. |d 60000 |d 62700 |e 60000PW122148924 |e 62700PW122148924 |k 0/60000/ |k 1/60000/62700/ |p 3 |y j | ||
| 998 | |g 1077188838 |a Brenner, David |m 1077188838:Brenner, David |d 60000 |d 62700 |e 60000PB1077188838 |e 62700PB1077188838 |k 0/60000/ |k 1/60000/62700/ |p 1 |x j | ||
| 999 | |a KXP-PPN1753282519 |e 3903133817 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 07.04.2021"],"relHost":[{"title":[{"subtitle":"official journal of the German Neurological Society","title":"Neurological research and practice","title_sort":"Neurological research and practice"}],"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["Volume 1, issue 1 (December 2019)-"],"language":["eng"],"note":["Gesehen am 25. März 2019"],"type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"display":"Deutsche Gesellschaft für Neurologie","role":"isb"}],"part":{"volume":"2","pages":"1-13","text":"2(2020), Artikel-ID 25, Seite 1-13","extent":"13","year":"2020"},"origin":[{"dateIssuedDisp":"[2019]-","publisher":"BioMed Central","publisherPlace":"[London]"}],"id":{"eki":["1038162947"],"issn":["2524-3489"],"zdb":["2947493-0"]},"disp":"Gene specific therapies the next therapeutic milestone in neurologyNeurological research and practice","recId":"1038162947"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"physDesc":[{"extent":"13 S."}],"title":[{"title":"Gene specific therapies","subtitle":"the next therapeutic milestone in neurology","title_sort":"Gene specific therapies"}],"person":[{"display":"Brenner, David","family":"Brenner","role":"aut","given":"David"},{"family":"Ludolph","role":"aut","given":"Albert C.","display":"Ludolph, Albert C."},{"family":"Weishaupt","role":"aut","given":"Jochen H.","display":"Weishaupt, Jochen H."}],"recId":"1753282519","name":{"displayForm":["David Brenner, Albert C. Ludolph and Jochen H. Weishaupt"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"2020 Sept. 8"}],"id":{"doi":["10.1186/s42466-020-00075-z"],"eki":["1753282519"]}} | ||
| SRT | |a BRENNERDAVGENESPECIF2020 | ||